Apollomics Class A Stock Today
| APLM Stock | 7.96 0.01 0.13% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Apollomics is selling at 7.96 as of the 20th of March 2025; that is 0.13 percent down since the beginning of the trading day. The stock's lowest day price was 7.49. Apollomics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Moving together with Apollomics Stock
Moving against Apollomics Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Apollomics Stock Highlights
| CEO CoFounder | GuoLiang Yu |
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Apollomics Class A (APLM) is traded on NASDAQ Exchange in USA. It is located in 989 East Hillsdale Blvd, Foster City, CA, United States, 94404 and employs 45 people. Apollomics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.52 M. Apollomics Class A conducts business under Biotechnology sector and is part of Health Care industry. The entity has 110.27 M outstanding shares of which 6.94 K shares are presently shorted by private and institutional investors with about 0.17 trading days to cover.
Apollomics generates negative cash flow from operations
Check Apollomics Probability Of Bankruptcy
Ownership AllocationApollomics holds a total of 110.27 Million outstanding shares. Apollomics Class A retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Apollomics Ownership Details
Apollomics Class A Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Apollomics market risk premium is the additional return an investor will receive from holding Apollomics long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.30) | |||
| Total Risk Alpha | 0.2824 | |||
| Treynor Ratio | 0.1517 |
Apollomics Stock Against Markets
Apollomics Corporate Management
| Matthew Plunkett | Chief Officer | Profile | |
| Chinglin Lai | Senior Management | Profile | |
| KinHung MD | Chief Officer | Profile | |
| Lijuan Wang | Chief China | Profile |
Already Invested in Apollomics Class A?
The danger of trading Apollomics Class A is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Apollomics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Apollomics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Apollomics Class A is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Apollomics Class A is a strong investment it is important to analyze Apollomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Apollomics' future performance. For an informed investment choice regarding Apollomics Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apollomics Class A. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apollomics. If investors know Apollomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apollomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Apollomics Class A is measured differently than its book value, which is the value of Apollomics that is recorded on the company's balance sheet. Investors also form their own opinion of Apollomics' value that differs from its market value or its book value, called intrinsic value, which is Apollomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apollomics' market value can be influenced by many factors that don't directly affect Apollomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apollomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apollomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apollomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.